New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 27, 2012
08:05 EDTCPRXCatalyst Pharmaceutical receives Nasdaq Staff Deficiency Letter
Catalyst Pharmaceutical announced that it received a Nasdaq Staff Deficiency Letter, dated December 24, indicating that the company is not in compliance with the Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market.
News For CPRX From The Last 14 Days
Check below for free stories on CPRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
09:00 EDTCPRXCatalyst Pharmaceutical price target raised to $5 from $3.50 at Roth Capital
Roth Capital increased its price target on Catalyst to reflect what it sees as greater pricing power opportunities for Firdapse and the re-entry of CPP-115 into the clinic. Evaluating the potential outcome of a Phase 3 trial of Firdapse expected at the end of this month, the firm says the decision by all patients enrolled to continue treatment in the 2-year open label part of the trial is positive. However, Roth warns that the data poses a binary risk to the stock. It keeps a Buy rating on the shares. .
September 15, 2014
08:32 EDTCPRXCatalyst Pharmaceutical price target raised to $13 from $5 at H.C. Wainwright
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use